Notably, a recent report revealed that concomitant blockage of EGFR and MEK by combination treatment of pimasertib (MEK1/2 inhibitor) with cetuximab was proven to be effective against CRC cells harboring KRAS mutation [48]. This evidence concerns the gene MAP2K1 and colorectal carcinoma.